MX2022014754A - Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central. - Google Patents

Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central.

Info

Publication number
MX2022014754A
MX2022014754A MX2022014754A MX2022014754A MX2022014754A MX 2022014754 A MX2022014754 A MX 2022014754A MX 2022014754 A MX2022014754 A MX 2022014754A MX 2022014754 A MX2022014754 A MX 2022014754A MX 2022014754 A MX2022014754 A MX 2022014754A
Authority
MX
Mexico
Prior art keywords
fgf21
growth factor
nervous system
central nervous
fibroblast growth
Prior art date
Application number
MX2022014754A
Other languages
English (en)
Inventor
Pallares Claudia Jambrina
Cenzano Veronica Jimenez
Costa Ignasi Grass
Tubert Maria Fatima Bosch
Puigdomenech Ivet Elias
Victor Sacristan Fraile
Original Assignee
UNIV AUTòNOMA DE BARCELONA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIV AUTòNOMA DE BARCELONA filed Critical UNIV AUTòNOMA DE BARCELONA
Publication of MX2022014754A publication Critical patent/MX2022014754A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Abstract

En el presente documento se describe un constructo génico que comprende una secuencia de nucleótidos que codifica un factor de crecimiento de fibroblastos 21 (FGF21), para usarse en el tratamiento y/o la prevención de un trastorno o enfermedad del sistema nervioso central (CNS), o una afección asociada al mismo.
MX2022014754A 2020-05-26 2021-05-26 Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central. MX2022014754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382442 2020-05-26
PCT/EP2021/064060 WO2021239815A1 (en) 2020-05-26 2021-05-26 Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders

Publications (1)

Publication Number Publication Date
MX2022014754A true MX2022014754A (es) 2023-01-16

Family

ID=70921969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014754A MX2022014754A (es) 2020-05-26 2021-05-26 Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central.

Country Status (10)

Country Link
US (1) US20230201306A1 (es)
EP (1) EP4157317A1 (es)
JP (1) JP2023528590A (es)
KR (1) KR20230017845A (es)
CN (1) CN115916985A (es)
AU (1) AU2021281506A1 (es)
CA (1) CA3179874A1 (es)
IL (1) IL298532A (es)
MX (1) MX2022014754A (es)
WO (1) WO2021239815A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079317A1 (en) * 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6548286B1 (en) 1997-04-14 2003-04-15 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
WO1998051810A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
ATE438414T1 (de) 2000-06-01 2009-08-15 Univ North Carolina Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
JP2020530977A (ja) * 2017-05-24 2020-11-05 ウニベルシダッド アウトノマ デ バルセロナ 線維芽細胞増殖因子２１（ｆｇｆ２１）コーディング配列を含むウイルス発現コンストラクト

Also Published As

Publication number Publication date
CN115916985A (zh) 2023-04-04
AU2021281506A1 (en) 2023-02-02
JP2023528590A (ja) 2023-07-05
WO2021239815A1 (en) 2021-12-02
EP4157317A1 (en) 2023-04-05
US20230201306A1 (en) 2023-06-29
KR20230017845A (ko) 2023-02-06
IL298532A (en) 2023-01-01
CA3179874A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
HUP0203863A2 (hu) Az axon növekedés Nogo-receptor közvetítette blokkolása
MX2022014754A (es) Terapia genica del factor de crecimiento de fibroblastos 21 (fgf21) para trastornos del sistema nervioso central.
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
WO2003002596A3 (en) Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
IL196151A (en) Use of a pharmaceutical awning protein that binds to beta-glucoserbrosideis in the preparation of a drug for the treatment of a disorder associated with degeneration of nerve tissue
MX2021005824A (es) Genoterapia con factor 21 de crecimiento de fibroblastos (fgf21).
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
DK160190A (da) Neurit-vaekstregulerende faktorer
AU2001284792A1 (en) Augmented cognitive training
MX2022001623A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
HK1102598A1 (en) Therapeutic use of a growth factor, nsg33
ES2105766T3 (es) Levobupivacaina utilizada en el tratamiento del dolor cronico.
WO2018151811A3 (en) Use of tgf alpha for the treatment of diseases and disorders
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
MX2022011518A (es) Metodos para tratar deambulacion asociada a proteinopatia.
Mata et al. Olanzapine: concordant response in monozygotic twins with schizophrenia
MX2023004170A (es) Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac).
HU9402647D0 (en) The use of 4-aminopyridine for treating neurological conditions
Grossarth-Maticek et al. RETRACTED: Prophylactic effects of psychoanalysis on cancer-prone and coronary heart disease-prone probands, as compared with control groups and behaviour therapy groups
Burke et al. Treatment of clozapine sedation.
MX2020012925A (es) Producto inmunogeno que comprende il-4 y/o il-13 para el tratamiento de enfermedades asociadas con la expresion o actividad aberrante de il-4 y/o il 13.
MX2023000517A (es) Polimorfos de un agonista del receptor a del acido gamma-aminobutirico (gabaa) alfa 5 y metodos de uso en el tratamiento del deterioro cognitivo.
Horn et al. Preventing violence in schizophrenia: Why do delusional familiarity disorders remain so unfamiliar?
WO2023220737A3 (en) Oligonucleotides having a synthetic backbone and synthesis thereof
Berg Invited Editorial Commentary Stopping Antiepileptic Drugs after Successful Surgery: What Do We Know? and What Do We Still Need to Learn?